In vitro comparative analysis of Circulating Tumour Cells detection in liquid biopsy for the diagnosis of pancreatic adenocarcinoma

Pancreatology ◽  
2017 ◽  
Vol 17 (3) ◽  
pp. S23
Author(s):  
Etienne Buscail ◽  
Olivier Degrandi ◽  
Charline Caumont ◽  
Jean-Philippe Merlio ◽  
François Moreau-Gaudry ◽  
...  
Pancreatology ◽  
2018 ◽  
Vol 18 (4) ◽  
pp. S9
Author(s):  
Etienne Buscail ◽  
Charline Caumont ◽  
Catherine Alix-Panabières ◽  
Pascaline Quincy ◽  
Marion Marty ◽  
...  

Author(s):  
Yujun Tang ◽  
Yishi Lu ◽  
Yuan Chen ◽  
Lei Luo ◽  
Lei Cai ◽  
...  

Abstract Background Circulating tumour cells (CTCs), especially mesenchymal CTCs, are important determinants of metastasis, which leads to most recurrence and mortality in hepatocellular carcinoma (HCC). However, little is known about the underlying mechanisms of CTC colonisation in pre-metastatic niches. Methods Detection and classification of CTCs in patients were performed using the CanPatrol™ system. A lentiviral vector expressing Prrx1-targeting shRNA was constructed to generate a stable HCC cell line with low expression of Prrx1. The effect of Prrx1 knockdown on stemness, migration, and drug resistance of the cell line was assessed, including involvement of SDF-1/CXCR4 signalling. Promising clinical applications of an inhibitor of STAT3 tyrosine phosphorylation, C188–9, and specific blockade with CXCR4 antibody were explored. Results The number of mesenchymal CTCs in blood was closely associated with tumour recurrence or metastasis. Pre-metastatic niche-derived SDF-1 could downregulate Prrx1, which induced the stemness, drug resistance, and increased expression of CXCR4 in HCC cells through the STAT3 pathway in vitro. In vivo, mice bearing tumours of Prrx1 low-expressing cells had significantly shorter survival. In xenograft tumours and clinical samples, loss of Prrx1 was negatively correlated with increased expression of CXCR4 in lung metastatic sites compared with that in the primary foci. Conclusions These findings demonstrate that decreased expression of Prrx1 stimulates SDF-1/CXCR4 signalling and contributes to organ colonisation with blood CTCs in HCC. STAT3 inhibition and specific blockade of CXCR4 have clinical potential as therapeutics for eliminating organ metastasis in advanced HCC.


2017 ◽  
Vol 77 (12) ◽  
pp. 1291-1298 ◽  
Author(s):  
Arkadius Polasik ◽  
Marie Tzschaschel ◽  
Fabienne Schochter ◽  
Amelie de Gregorio ◽  
Thomas Friedl ◽  
...  

AbstractDissemination of tumour cells and the development of solid metastases occurs via blood vessels and lymphatics. Circulating tumour cells (CTCs) and circulating tumour DNA (ctDNA) can be detected in venous blood in patients with early and metastatic breast cancer, and their prognostic relevance has been demonstrated on numerous occasions. Repeated testing for CTCs and ctDNA, or regular so-called “liquid biopsy”, can be performed easily at any stage during the course of disease. Additional molecular analysis allows definition of tumour characteristics and heterogeneity that may be associated with treatment resistance. This in turn makes personalised, targeted treatments possible that may achieve both improved overall survival and quality of life.


2014 ◽  
Vol 25 ◽  
pp. iv77
Author(s):  
P. Basile ◽  
D. Sefrioui ◽  
F. Blanchard ◽  
S. Lecleire ◽  
F. Clatot ◽  
...  

2015 ◽  
Vol 7 (1) ◽  
pp. 53-58
Author(s):  
Christopher D. Hart ◽  
Francesca Galardi ◽  
Francesca De Luca ◽  
Marta Pestrin ◽  
Angelo Di Leo

2019 ◽  
Vol 65 (4) ◽  
pp. 31-36
Author(s):  
Anna Bogacz ◽  
Marlena Wolek ◽  
Aleksandra Górska ◽  
Ewa Leporowska ◽  
Danuta Procyk ◽  
...  

SummaryIntroduction: Plants are a rich source of healing substances. Cancer is a leading cause of death worldwide while breast cancer is the most common cancer among women. Circulating tumour cells (CTCs) are potential founder cells for metastasis. Therefore, their assessment may be used for monitoring of treatment as well as detecting cancer metastatis. Hence, it is suggested that the number of CTCs may be a valuable tumour biomarker during therapy.Objective: The purpose of this study was to detect CTCs in breast cancer and to validate the method of assessment of CTC count using CytoTrack CT11 technology.Methods: MCF-7 cells were sorted by a FACSARIA flow cytometer from blood samples derived from patients who have not been diagnosed with cancer. Identification and quantitative assessment of MCF-7 cells in blood samples were determined by flow sorting. Then, blood samples containing MCF-7 cells or without MCF-7 were scanned with the use of an automated fluorescence scanning microscope.Results: In in vitro model analysing the glass CytoDisc™ with stained MCF-7 cells, we noted the correlation between the amount of observed tumour cells and expected number of tumour cells. Moreover, coefficient of variation in case of the recovery rate of the assumed number of MCF-7 cells was 30%, 17%, 18% and 15%, respectively.Conclusion: Our study suggest that CTCs could be predictive factor in patients with metastatic cancer especially in breast cancer.


Cancers ◽  
2021 ◽  
Vol 13 (17) ◽  
pp. 4446
Author(s):  
Cláudia Lopes ◽  
Paulina Piairo ◽  
Alexandre Chícharo ◽  
Sara Abalde-Cela ◽  
Liliana R. Pires ◽  
...  

HER2 is a prognostic and predictive biomarker in breast cancer, normally assessed in tumour biopsy and used to guide treatment choices. Circulating tumour cells (CTCs) escape the primary tumour and enter the bloodstream, exhibiting great metastatic potential and representing a real-time snapshot of the tumour burden. Liquid biopsy offers the unique opportunity for low invasive sampling in cancer patients and holds the potential to provide valuable information for the clinical management of cancer patients. This study assesses the performance of the RUBYchip™, a microfluidic system for CTC capture based on cell size and deformability, and compares it with the only FDA-approved technology for CTC enumeration, CellSearch®. After optimising device performance, 30 whole blood samples from metastatic breast cancer patients were processed with both technologies. The expression of HER2 was assessed in isolated CTCs and compared to tissue biopsy. Results show that the RUBYchipTM was able to isolate CTCs with higher efficiency than CellSearch®, up to 10 times more, averaging all samples. An accurate evaluation of different CTC subpopulations, including HER2+ CTCs, was provided. Liquid biopsy through the use of the RUBYchipTM in the clinic can overcome the limitations of histological testing and evaluate HER2 status in patients in real-time, helping to tailor treatment during disease evolution.


Sign in / Sign up

Export Citation Format

Share Document